Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Carotuximab (Primary) ; Bevacizumab
- Indications Choriocarcinoma
- Focus Therapeutic Use
- Sponsors TRACON Pharmaceuticals
- 16 May 2017 Planned End Date changed from 1 Mar 2016 to 1 Nov 2017.
- 16 May 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2016 Updated data presented at the Annual Meeting of the Society of Gynecologic Oncology 2016, according to a TRACON Pharmaceuticals media release.